JPMA's Vision for 2035
Drug Discovery Innovation for Japan and the World
Amidst the drastically changing environment surrounding the JPMA's Vision for 2035, the JPMA has formulated a new "JPMA's Vision for 2035". The vision consists of the three pillars of Innovation, Access, and Trust, and we would like to introduce our vision for the future and our efforts to realize it.
From JPMA
Interview with Asuka Miyabashira, New Chairman
The future of the JPMA industry as envisioned by Mr. Miyabashira, who will assume the position of JPMA President in May 2025. He spoke about his determination to transform Japan into an attractive market by promoting co-creation, viewing the three crises of declining drug discovery capabilities, stable supply problems, and tight healthcare finances as "opportunities".
My Committee
vol.3 Code Compliance Committee
The Code Compliance Committee, which plays a key role in enhancing the credibility of the pharmaceutical industry, is at the forefront of activities to address five key issues and share a high ethical standard for patients throughout the industry, and the passion of the committee members.
The Pharmaceutical Industry from a Factual Perspective
Characteristics of New Drugs Approved in Japan
New drugs approved in Japan before the market launch are often regarded as "country drugs" that are not accepted overseas. The Office of Pharmaceutical Industry ResearchA comprehensive survey conducted by the Japan Pharmaceutical Manufacturers Association (JMPIA) reveals the reality and usefulness of these drugs. We will reconsider our view of "country drugs.
Key words to keep in mind
The Impact of the New U.S. Administration on the Pharmaceutical Industry
The Japanese pharmaceutical industry, which has been promoting globalization in recent years, is now facing a new challenge: heightened geopolitical risks under the new U.S. administration. Experts will give an urgent Explanation of what risks are of concern in drug development and manufacturing, and how companies should respond.
Topics
Introducing various topics within the association
The latest developments, including a press conference by new JPMA President Miyabashira, the 14th APAC meeting, and the 2025 revision of the JPMA Code of Practice, will be presented.
Please click here to send us your comments on the renewed Newsletter. ／Readers' Questionnaire